US · PHARMACEUTICAL PREPARATIONS · SMALL CAP
Procyon Corporation PCYN
14 fiscal years on record · USD · FY2023 reported
SEC FILINGS ONLY
Revenue · FY2023
$5.0M
▲ 6.4% vs FY2022
EPS · FY23
$-0.04
Dividend / sh · FY23
—
Payout · FY23
—
ROE · FY23
-13.9%
Net margin · FY23
-6.8%
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 5.0M
Revenue, FY2023 · full 14-year series below
Revenue
Net income
The company lost 7 cents on every revenue dollar this year.
Per share
USD -0.04
Diluted EPS, FY2023
EPS
The company pays no cash dividend.
Profitability
-13.9%
Return on equity, FY2023
ROE
Operating margin-4.6%
Net margin-6.8%
Return on assets-10.1%
Each USD of equity lost 14 cents this year.
Returned to shareholders
—
returned in FY2023 · dividends + net buybacks
Dividends paid—
Net buybacks—
Share of profit—
Consecutive raises—
Growth
+3.5% a year
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
+1.8%
+3.5%
+5.8%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
0.01B
Shares outstanding, FY2023
Change, 5 years+0.4%
Change, 10 years+0.7%
The share count grew 0% in five years — the same company, cut into more, smaller slices.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 3.2M
total assets, end of FY2023
Total assetsUSD 3.2M
EquityUSD 2.3M
Current ratio3.08×
Equity funds 71% of total assets.
History
14 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
Revenue $B
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
Operating income $B
−0.0
−0.0
−0.0
0.0
0.0
0.0
0.0
0.0
−0.0
−0.0
0.0
−0.0
0.0
0.0
EBITDA $B
−0.0
−0.0
−0.0
0.0
0.0
0.0
0.0
0.0
−0.0
−0.0
0.0
0.0
0.0
0.0
Income tax $B
0.0
−0.0
−0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
−0.0
0.0
0.0
0.0
Net income $B
−0.0
−0.0
−0.0
0.0
0.0
0.0
−0.0
0.0
0.0
−0.0
0.0
−0.0
0.0
0.0
EPS, diluted $
−0.04
−0.01
−0.03
0.08
0.01
0.00
−0.03
0.00
0.01
−0.03
0.00
−0.02
0.01
0.02
Dividend / sh $
·
·
·
·
·
·
·
·
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
·
·
·
·
·
·
·
·
ROE %
−13.9
−1.9
−7.6
27.5
5.3
1.3
−11.8
0.5
5.0
−9.6
1.0
−4.3
5.4
8.3
Shares out B
0.01
0.01
0.01
0.01
0.01
0.01
0.01
0.01
0.01
0.01
0.01
0.01
0.01
0.01
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
53 of 53
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed